Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, 20814;
Computational Chemistry and Molecular Biophysics Unit, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, 21224;
Computational Chemistry and Molecular Biophysics Unit, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, 21224;
University of North Carolina, Chapel Hill, NC, 27599;
University of North Carolina, Chapel Hill, NC, 27599;
Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, 20814;
Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, 20814;
University of North Carolina, Chapel Hill, NC, 27599;
Neurotherapeutic Development Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, 20814;
Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, 20814;
National Center for Advancing Translational Sciences, Rockville, MD, 20892;
National Center for Advancing Translational Sciences, Rockville, MD, 20892;
Columbia University, New York, NY, 10032;
Neurotherapeutic Development Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, 20814;